Cargando…

Baricitinib for COVID-19: a suitable treatment?

Detalles Bibliográficos
Autores principales:	Favalli, Ennio G, Biggioggero, Martina, Maioli, Gabriella, Caporali, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270794/ https://www.ncbi.nlm.nih.gov/pubmed/32251638 http://dx.doi.org/10.1016/S1473-3099(20)30262-0

Ejemplares similares

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs
por: Favalli, Ennio Giulio, et al.
Publicado: (2014)

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
por: Favalli, Ennio Giulio, et al.
Publicado: (2023)

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Baricitinib for COVID-19: a suitable treatment? – Authors' reply
por: Richardson, Peter J, et al.
Publicado: (2020)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
por: Biggioggero, Martina, et al.
Publicado: (2019)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
por: Biggioggero, Martina, et al.
Publicado: (2018)

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
por: Becciolini, Andrea, et al.
Publicado: (2016)

Structural integrity versus radiographic progression in rheumatoid arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2015)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
por: Becciolini, Andrea, et al.
Publicado: (2017)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future
por: Biggioggero, Martina, et al.
Publicado: (2018)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
por: Favalli, Ennio Giulio, et al.
Publicado: (2018)

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

COVID-19 infection and rheumatoid arthritis: Faraway, so close!
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country
por: Licciardi, Francesco, et al.
Publicado: (2020)

Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
por: Favalli, Andrea, et al.
Publicado: (2022)

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
por: Spinelli, Francesca Romana, et al.
Publicado: (2022)

Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
por: Thoms, Brendan L., et al.
Publicado: (2022)

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Pharmacokinetics of baricitinib in critically ill COVID-19 patients
por: Massart, Nicolas, et al.
Publicado: (2023)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Current Status of Baricitinib as a Repurposed Therapy for COVID-19
por: Saber-Ayad, Maha, et al.
Publicado: (2021)

Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019)

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
por: Smith, Daniel P., et al.
Publicado: (2021)

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
por: Goletti, Delia, et al.
Publicado: (2021)

NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
Publicado: (2021)

Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
por: Kojima, Yuichi, et al.
Publicado: (2022)

Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review
por: Dupuis, Derma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8b54v7r8vdnf3su0slgda6huda